Esperion Therapeutics Inc at Needham Healthcare Conference Transcript
Hello, everybody. My name is Chad Messer. I'm a senior biotech analyst here at Needham & Company. It is my pleasure today to be speaking with Tim Mayleben, the CEO of Esperion.
And Tim, let me just start by congratulating you guys for approval and launch of a drug in this tremendous environment. Maybe you can start by talking about the experience and how things are going.
Yes, thank you, Chad. So this was a team effort, as I think most things, if not all things, are at Esperion. And as you noted, we recently received FDA approval for both NEXLETOL and NEXLIZET in February, and then most recently within the last week or so we obtained approval for the EU for both medicines. They have different trade names there, NILEMDO and NUSTENDI, but both are now approved. And our commercial partner in the EU, Daiichi Sankyo Europe, is committed to making those available to patients in the EU here over the summer.
So as you noted, back here in the US, we
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |